5. (Currently amended): The composition ~~Preparation~~ as claimed in claim 1, characterized in that
[[it]] the anthracyclines comprise[[s]] at least one of doxorubicin, daunomycin, actinomycin D [[or/]]and mitoxantrone.

6. (Currently amended): The composition ~~Preparation~~ as claimed in claim 1, characterized in that
[[it]] the platinum complexes comprise[[s]] at least one of cis-platinum, oxaliplatinum [[or/]]and carboplatinum.

7. (Currently amended): A process ~~Process~~ for producing the pharmaceutical composition ~~preparations~~ as claimed in claim 1,
characterized in that
the active substances ~~optionally together with common pharmaceutical carrier substances or auxiliary substances are mixed and~~ are processed into oral or parenteral forms of administration.

8. (Withdrawn): Use of in particular a compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes and anthracyclines to produce an agent for an antineoplastic therapy.

9. (Withdrawn): Method for treating cancer and other diseases which are associated with abnormal cell proliferation,
characterized in that
at least one compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes or anthracyclines are administered in a molar ratio between 1:10 to 1:1000 and 10:1 to 1000:1, where the doses to be administered daily are 0.005 – 100 mg/kg body weight per individual component.

Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

Listing of Claims:

1. (Currently amended): A ~~Combined~~ pharmaceutical composition ~~preparation~~ for cancer therapy comprising as active substances:
   a) at least one compound having glutaminase activity; and
   b) at least one antineoplastic agent selected from the group consisting of platinum complexes and anthracyclines.

2. (Currently amended): The composition ~~Preparation~~ as claimed in claim 1, characterized in that
   the at least one compound having glutaminase activity is a glutaminase, glutaminase-asparaginase, glutaminase analogue, derivative or modification thereof ~~of the same~~ and is either of natural origin or is produced synthetically.

3. (Currently amended): The composition ~~Preparation~~ as claimed in claim 2, characterized in that
   the at least one compound having glutaminase activity is [[from]] Pseudomonas, ~~and is~~ preferably Pseudomonas 7A glutaminase-asparaginase.

4. (Currently amended): The composition ~~Preparation~~ as claimed in claim 1, characterized in that
   the at least one compound having glutaminase activity is modified ~~preferably~~ with polyethylene glycol.

10 (New): The process as claimed in claim 7,
characterized in that
the active substances are mixed together with common pharmaceutical carrier substances or auxiliary substances.